Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Evolus Inc (EOLS)

Evolus Inc (EOLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,057,314
  • Shares Outstanding, K 62,600
  • Annual Sales, $ 202,090 K
  • Annual Income, $ -61,690 K
  • 60-Month Beta 1.31
  • Price/Sales 5.24
  • Price/Cash Flow N/A
  • Price/Book 57.14
Trade EOLS with:

Options Overview Details

View History
  • Implied Volatility 49.12% ( +22.61%)
  • Historical Volatility 44.44%
  • IV Percentile 30%
  • IV Rank 24.48%
  • IV High 144.68% on 07/17/24
  • IV Low 18.15% on 05/21/24
  • Put/Call Vol Ratio 0.11
  • Today's Volume 49
  • Volume Avg (30-Day) 335
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 6,210
  • Open Int (30-Day) 4,895

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.22
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.29 +12.98%
on 08/19/24
17.70 -8.79%
on 09/16/24
+1.80 (+12.51%)
since 08/16/24
3-Month
10.24 +57.67%
on 06/26/24
17.70 -8.79%
on 09/16/24
+5.51 (+51.74%)
since 06/18/24
52-Week
7.44 +117.00%
on 11/01/23
17.70 -8.79%
on 09/16/24
+6.77 (+72.12%)
since 09/18/23

Most Recent Stories

More News
Why Shares of Evolus Are Jumping Thursday

The stock climbed on record second-quarter revenue and a raise in full-year guidance.

EOLS : 16.22 (-3.97%)
Twitter Faces Threats From AI and Threads

AI is changing the open internet landscape, and Meta's new Threads app is looking to take a bite out of Twitter's audience.

META : 537.95 (+0.30%)
GOOGL : 159.81 (+0.31%)
ADBE : 508.13 (-1.34%)
GOOG : 160.81 (+0.33%)
EOLS : 16.22 (-3.97%)
DIS : 93.58 (+0.78%)
PM : 120.96 (-1.84%)
MODG : 10.60 (+3.21%)
GOLF : 63.32 (-0.09%)
TWTR : 53.70 (+0.66%)
WMT : 79.03 (+0.55%)
Evolus to Report First Quarter 2023 Results and Provide Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its first quarter 2023 financial...

EOLS : 16.22 (-3.97%)
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the fourth quarter and full...

EOLS : 16.22 (-3.97%)
Evolus to Participate in the Barclays Global Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating...

EOLS : 16.22 (-3.97%)
Evolus Initiates Nuceiva® Launch in Germany and Austria

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has commenced the commercial launch of Nuceiva ® (botulinum toxin...

EOLS : 16.22 (-3.97%)
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its fourth quarter and year end...

EOLS : 16.22 (-3.97%)
Evolus Not Affected by Recent Korean Court Ruling

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, issued the following statement.

EOLS : 16.22 (-3.97%)
Evolus to Participate in the SVB Securities Global Biopharma Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating...

EOLS : 16.22 (-3.97%)
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today presented interim data from its Phase II clinical study evaluating...

EOLS : 16.22 (-3.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus,...

See More

Key Turning Points

3rd Resistance Point 17.58
2nd Resistance Point 17.35
1st Resistance Point 17.12
Last Price 16.22
1st Support Level 16.66
2nd Support Level 16.43
3rd Support Level 16.20

See More

52-Week High 17.70
Last Price 16.22
Fibonacci 61.8% 13.78
Fibonacci 50% 12.57
Fibonacci 38.2% 11.36
52-Week Low 7.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar